"A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma"
Trial Description
The purpose of this study is to determine whether relatlimab in combination with nivolumab is
more effective than nivolumab by itself in treating unresectable melanoma or melanoma that
has spread.
Eligibility Requirements
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV
melanoma, per the AJCC staging system
- Participants must not have had prior systemic anticancer therapy for unresectable or
metastatic melanoma
- Tumor tissue from an unresectable or metastatic site of disease must be provided for
biomarker analyses
Exclusion Criteria:
- Participants must not have active brain metastases or leptomeningeal metastases
- Participants must not have uveal melanoma
- Participants must not have an active, known, or suspected autoimmune disease
Other protocol defined inclusion/exclusion criteria could apply